FCCC LOGO Faculty Publications
Miyamoto DT , Abbosh PH , West CML , Mouw KW
Bladder preservation: Translating discovery for clinical impact in urothelial cancer
Urologic Oncology-Seminars and Original Investigations. 2021 Apr;39(4) :201-208
PMID: WOS:000627873500002   
Back to previous list
Abstract
Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer. (C) 2020 Elsevier Inc. All rights reserved.
Notes
Miyamoto, David T. Abbosh, Philip H. West, Catharine M. L. Mouw, Kent W. Mouw, Kent/0000-0001-7939-7343 1873-2496